Caffeine consumption and risk of dyskinesia in CALM-PD

Movement Disorders

Volumn 28, Issue 3, 2013, Pages 380-383

  Wills, Anne Marie A ^a   Eberly, Shirley ^b   Tennis, Marsha ^a   Lang, Anthony E ^c   Messing, Susan ^b   Togasaki, Daniel ^d   Tanner, Caroline M ^e   Kamp, Cornelia ^f   Chen, Jiang Fan ^g   Oakes, David ^b   McDermott, Michael P ^b,f   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e PARKINSON S INSTITUTE   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g BOSTON UNIVERSITY   (United States)

Author keywords

Adenosine; Caffeine; Dyskinesia; Parkinson's disease; PD

Indexed keywords

CAFFEINE; LEVODOPA; PLACEBO; PRAMIPEXOLE;

ARTICLE; COFFEE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSKINESIA; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK;

ADENOSINE A2 RECEPTOR ANTAGONISTS; AGED; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CAFFEINE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK;

EID: 84875535930     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25319     Document Type: Article

References (21)

1. Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol. 2003;184:285-294.
2. Xiao D, Bastia E, Xu YH, et al. Forebrain adenosine A2A receptors contribute to L-3, 4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci. 2006;26:13548-13555.
3. Fredduzzi S, Moratalla R, Monopoli A, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci. 2002;22:1054-1062.
4. Xiao D, Cassin JJ, Healy B, et al. Deletion of adenosine A or A(A) receptors reduces L-3, 4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Res. 2010;1367:310-318.
5. Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, DiPaolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain. 2004;127:1075-1084.
6. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology. 2011;76:1811-1816.
7. Mishina M, Ishiwata K, Naganawa M, et al. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PLoS One. 2011;6:e17338.
8. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010;25:1437-1443.
9. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177-2185.
10. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10:221-229.
11. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295-302.
12. Shoulson I, Chase T. Caffeine and the antiparkinsonian response to levodopa or piribedil. Neurology. 1975;25:722-724.
13. Gottwald MD, Aminoff MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol. 2011;69:919-927.
14. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA. 2000;284:1931-1938.
15. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol. 2000;23:34-44.
16. Parkinson Study Group. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66:563570.
17. Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord. 2007;22:13171319.
18. Simon DK, Swearingen CJ, Hauser RA, et al. Caffeine and progression of Parkinson disease. Clin Neuropharmacol. 2008;31:189-196.
19. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: A randomized controlled trial. Neurology. 2012;79:651-658.
20. Altman RD, Lang AE, Postuma RB. Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord. 2011;26:2427-2431.
21. Hamza TH, Chen H, Hill-Burns EM, et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet. 2011;7:e1002237.